Ventilator-associated pneumonia caused by Pseudomonas aeruginosa: Cap your needles!

Critical Care Medicine

Volumn 40, Issue 8, 2012, Pages 2503-2504

  Hauser, Alan R ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

KB001; PcrV; Pseudomonas aeruginosa; treatment; type III secretion; ventilator associated pneumonia; virulence

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL PROTEIN; EFFECTOR PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; KB 001; PEGYLATED IMMUNOGLOBULIN F(AB) FRAGMENT; PHOSPHOLIPID; PLACEBO; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG;

ACTIN FILAMENT; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; BACTERIUM ISOLATE; DISEASE SEVERITY; DRUG MEGADOSE; DRUG TOLERABILITY; EDITORIAL; HUMAN; LOW DRUG DOSE; MOLECULAR PATHOLOGY; NEEDLE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS PNEUMONIA; QUORUM SENSING; SIGNAL TRANSDUCTION; TYPE III SECRETION SYSTEM; UNSPECIFIED SIDE EFFECT; VENTILATOR ASSOCIATED PNEUMONIA;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MALE; PNEUMONIA, VENTILATOR-ASSOCIATED; PSEUDOMONAS INFECTIONS;

EID: 84864187710     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318258e5bb     Document Type: Editorial

References (16)

1. Veesenmeyer JL, Hauser AR, Lisboa T, et al: Pseudomonas aeruginosa virulence and therapy: Evolving translational strategies. Crit Care Med 2009; 37:1777-1786.
2. Kipnis E, Sawa T, Wiener-Kronish J: Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Med Mal Infect 2006; 36:78-91. (Pubitemid 43294628)
3. Hauser AR: The type III secretion system of Pseudomonas aeruginosa: Infection by injection. Nat Rev Microbiol 2009; 7:654-665.
4. Hauser AR, Cobb E, Bodi M, et al: Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 2002; 30:521-528. (Pubitemid 34214611)
5. Roy-Burman A, Savel RH, Racine S, et al: Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 2001; 183:1767-1774. (Pubitemid 32523239)
6. El Solh AA, Akinnusi ME, Wiener-Kronish JP, et al: Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia. Am J Respir Crit Care Med 2008; 178:513-519.
7. El-Solh AA, Vora H, Knight PR3rd, et al: Diagnostic use of serum procalcitonin levels in pulmonary aspiration syndromes. Crit Care Med 2011; 39:1251-1256.
8. Aiello D, Williams JD, Majgier-Baranowska H, et al: Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion. Antimicrob Agents Chemother 2010; 54:1988-1999.
9. Grier MC, Garrity-Ryan LK, Bartlett VJ, et al: N-Hydroxybenzimidazole inhibitors of ExsA MAR transcription factor in Pseudomonas aeruginosa: In vitro anti-virulence activity and metabolic stability. Bioorg Med Chem Lett 2010; 20:3380-3383.
10. Frank DW, Vallis A, Wiener-Kronish JP, et al: Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis 2002; 186:64-73. (Pubitemid 34666915)
11. Goure J, Broz P, Attree O, et al: Protective anti-V antibodies inhibit Pseudomonas and Yersinia translocon assembly within host membranes. J Infect Dis 2005; 192:218-225. (Pubitemid 40993391)
12. Faure K, Fujimoto J, Shimabukuro DW, et al: Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat model. J Immune Based Ther Vaccines 2003; 1:1-9.
13. Sawa T, Yahr TL, Ohara M, et al: Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med 1999; 5:392-398. (Pubitemid 29180576)
14. Shime N, Sawa T, Fujimoto J, et al: Therapeutic administration of anti-PcrV F(ab')(2) in sepsis associated with Pseudomonas aeruginosa. J Immunol 2001; 167:5880-5886. (Pubitemid 33062782)
15. Neely AN, Holder IA, Wiener-Kronish JP, et al: Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge. Burns 2005; 31:153-158. (Pubitemid 40430869)
16. François B, Luyt C-E, Dugard A, et al: Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: A randomized, double-blind, placebo-controlled trial. Crit Care Med 2012; 40:2320-2326